参考文献/References:
[1] Hewlings SJ, Kalman DS. Curcumin:a review of its' effects on human health[J].Foods,2017,6(10):92.DOI:10.3390/foods6100092.
[2] Kotha RR, Luthria DL. Curcumin:biological, pharmaceutical, nutraceutical, and analytical aspects[J].Molecules,2019, 24(16):2930.DOI:10.3390/molecules24162930.
[3] Yan C,Zhang Y,Zhang X, et al. Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice[J].Biomed Pharmacother, 2018,105:274-281.DOI:10.1016/j.biopha.2018.05.135.
[4] Niu Y, He J, Ahmad H, et al. Curcumin attenuates insulin resistance and hepatic lipid accumulation in a rat model of intrauterine growth restriction through insulin signaling pathway and SREBPs[J].Br J Nutr,2019:1-29.DOI:10.1017/S0007114519001508.
[5] Kuo JJ, Chang HH, Tsai TH, et al. Curcumin ameliorates mitochondrial dysfunction associated with inhibition of gluconeogenesis in free fatty acid-mediated hepatic lipoapoptosis[J].Int J Mol Med,2012, 30(3):643-649.DOI:10.3892/ijmm.2012.1020.
[6] Zingg JM,Hasan ST,Nakagawa K,et al. Modulation of cAMP levels by high-fat diet and curcumin and regulatory effects on CD36/FAT scavenger receptor/fatty acids transporter gene expression[J].Biofactors,2017,43(1):42-53.DOI:10.1002/biof.1307.
[7] Um MY, Hwang KH, Ahn J, et al. Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase[J].Basic Clin Pharmacol Toxicol,2013,113(3):152-157.DOI:10.1111/bcpt.12076.
[8] Li YY, Tang D, Du YL, et al. Fatty liver mediated by peroxisome proliferator-activated receptor-α DNA methylation can be reversed by a methylation inhibitor and curcumin[J].J Dig Dis,2018,19(7):421-430.DOI:10.1111/1751-2980.12610.
[9] Al-Saud NBS. Impact of curcumin treatment on diabetic albino rats[J].Saudi J Biol Sci,2020,27(2):689-694.DOI:10.1016/j.sjbs.2019.11.037.
[10] Geng S,Wang S,Zhu W,et al. Curcumin suppresses JNK pathway to attenuate BPA-induced insulin resistance in LO2 cells[J].Biomed Pharmacother,2018,97:1538-1543.DOI:10.1016/j.biopha.2017.11.069.
[11] Kim Y,Rouse M,Gonzalez-Mariscal I, et al. Dietary curcumin enhances insulin clearance in diet-induced obese mice via regulation of hepatic PI3K-AKT axis and IDE, and preservation of islet integrity[J].Nutr Metab(Lond),2019,16:48.DOI:10.1186/s12986-019-0377-0.
[12] Weisberg S, Leibel R, Tortoriello DV. Proteasome inhibitors, including curcumin, improve pancreatic beta-cell function and insulin sensitivity in diabetic mice[J].Nutr Diabetes,2016,6:e205.DOI:10.1038/nutd.2016.13.
[13] Gheibi S, Gouvarchin Ghaleh HE, Motlagh BM, et al. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease[J].Biomed Pharmacother,2019,115:108938.DOI:10.1016/j.biopha.2019.108938.
[14] Liczbiński P,Michaowicz J,Bukowska B. Molecular mechanism of curcumin action in signaling pathways:review of the latest research[J].Phytother Res, 2020,[published online ahead of print].DOI:10.1002/ptr.6663.
[15] Zhai X,Qiao H,Guan W,et al. Curcumin regulates peroxisome proliferator-activated receptor-γ coactivator-1α expression by AMPK pathway in hepatic stellate cells in vitro[J].Eur J Pharmacol,2015,746:56-62.DOI:10.1016/j.ejphar.2014.10.055.
[16] Lee DE, Lee SJ, Kim SJ, et al. Curcumin ameliorates nonalcoholic fatty liver disease through inhibition of O-GlcNAcylation[J].Nutrients,2019,11(11):2702.DOI:10.3390/nu11112702.
[17] Kuo JJ, Chang HH, Tsai TH, et al. Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis[J].Int J Mol Med,2012,30(3):673-679.DOI:10.3892/ijmm.2012.1049.
[18] Wang L,Lv Y,Yao H,et al. Curcumin prevents the non-alcoholic fatty hepatitis via mitochondria protection and apoptosis reduction[J].Int J Clin Exp Pathol,2015,8(9):11503-11509.
[19] Zhong W, Qian K, Xiong J, et al. Curcumin alleviates lipopolysaccharide induced sepsis and liver failure by suppression of oxidative stress-related inflammation via PI3K/AKT and NF-kappaB related signaling[J].Biomed Pharmacother,2016,83:302-313.DOI:10.1016/j.biopha.2016.06.036.
[20] Alaaeddine N, Sidaoui J, Hilal G, et al. TNF-α messenger ribonucleic acid(mRNA)in patients with nonalcoholic steatohepatitis[J].Eur Cytokine Netw,2012,23(3):107-111.DOI:10.1684/ecn.2012.0313.
[21] Feng D,Zou J,Su D, et al. Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE mice by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-κB inflammation[J].Nutr Metab(Lond),2019,16:79.DOI:10.1186/s12986-019-0410-3.
[22] Kelany ME,Hakami TM,Omar AH. Curcumin improves the metabolic syndrome in high-fructose-diet-fed rats:role of TNF-α, NF-κB, and oxidative stress[J].Can J Physiol Pharmacol,2017,95(2):140-150.DOI:10.1139/cjpp-2016-0152
[23] Simental-Mendia LE, Cicero A FG, Atkin SL, et al. A systematic review and meta-analysis of the effect of curcuminoids on adiponectin levels[J].Obes Res Clin Pract,2019,13(4):340-344.DOI:10.1016/j.orcp.2019.04.003.
[24] Chen WJ, Cai B, Chen HT, et al. The role of ADIPOQ methylation in curcumin-administrated experimental nonalcoholic fatty liver disease[J].J Dig Dis,2016,17(12):829-836.DOI:10.1111/1751-2980.12431.
[25] Li C, Li J, Chen Y, et al. Effect of curcumin on visfatin and zinc-alpha2-glycoprotein in a rat model of non-alcoholic fatty liver disease[J].Acta Cir Bras,2016, 31(11):706-713.DOI:10.1590/S0102-865020160110000001.
[26] Loeffelholz C,Horn P,Birkenfeld AL, et al. Fetuin A is a predictor of liver fat in preoperative patients with nonalcoholic fatty liver disease[J].J Invest Surg,2016, 29(5):266-274.DOI:10.3109/08941939.2016.1149640.
[27] Oner-Iyidogan Y, Kocak H, Seyidhanoglu M, et al. Curcumin prevents liver fat accumulation and serum fetuin-A increase in rats fed a high-fat diet[J].J Physiol Biochem,2013,69(4):677-686.DOI:10.1007/s13105-013-0244-9.
[28] Su X, Kong Y, Peng D. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease[J].Clin Chim Acta,2019,498:30-37.DOI:10.1016/j.cca.2019.08.005.
[29] Zeng K, Tian L, Patel R, et al. Diet polyphenol curcumin stimulates hepatic Fgf21 production and restores its sensitivity in high-fat-diet-fed male mice[J].Endocrinology,2017, 158(2):277-292.DOI:10.1210/en.2016-1596.
[30] Panahi Y, Kianpour P, Mohtashami R, et al. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease:a randomized controlled trial[J].J Cardiovasc Pharmacol,2016,68(3):223-229.DOI:10.1097/FJC.0000000000000406.
[31] Jazayeri-Tehrani SA,Rezayat SM,Mansouri S, et al. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease(NAFLD):a double-blind randomized placebo-controlled clinical trial[J].Nutr Metab(Lond),2019,16:8.DOI:10.1186/s12986-019-0331-1.
[32] Saberi-Karimian M, Keshvari M, Ghayour-Mobarhan M,et al. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease:a randomized controlled trial[J].Complement Ther Med,2020,49:102322.DOI:10.1016/j.ctim.2020.102322.
[33] Cicero AFG, Sahebkar A, Fogacci F, et al. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices:a double-blind, placebo-controlled clinical trial[J].Eur J Nutr,2020,59(2):477-483.DOI:10.1007/s00394-019-01916-7.
[34] Saadati S, Hatami B, Yari Z, et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease[J].Eur J Clin Nutr,2019,73(3):441-449.DOI:10.1038/s41430-018-0382-9.
[35] Jafarirad S,Mansoori A,Adineh A,et al. Does turmeric/curcumin supplementation change anthropometric indices in patients with non-alcoholic fatty liver disease? a systematic review and meta-analysis of randomized controlled trials[J].Clin Nutr Res,2019,8(3):196-208.DOI:10.7762/cnr.2019.8.3.196.
相似文献/References:
[1]曹涵,曲伸.过氧化物酶体增殖物活化受体与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2014,(06):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
Cao Han,Qu Shen..Peroxisome proliferator-activated receptors and non-alcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2014,(06):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
[2]胡雅琴,包玉倩.维生素D对非酒精性脂肪性肝病的保护作用[J].国际内分泌代谢杂志,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
Hu Yaqin,Bao Yuqian..Protective effect of vitamin D on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
[3]聂秀玲,李明珍,孙丽荣.高尿酸血症与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2016,36(02):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
Nie Xiuling,Li Mingzhen,Sun Lirong..Hyperuricemia and non-alcoholic fatty liver[J].International Journal of Endocrinology and Metabolism,2016,36(06):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
[4]张洁,邸阜生.运动防治非酒精性脂肪性肝病的机制[J].国际内分泌代谢杂志,2016,36(06):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]
Zhang Jie,Di Fusheng..Mechanism of exercise on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2016,36(06):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]
[5]张雅楠,郗光霞,杨翠萍,等.自噬在非酒精性脂肪性肝病中的变化及作用[J].国际内分泌代谢杂志,2017,37(01):11.[doi:10.3760/cma.j.issn.1673-4157.2017.01.03]
Zhang Yanan*,Xi Guangxia,Yang Cuiping,et al.The change and function of autophagy in nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2017,37(06):11.[doi:10.3760/cma.j.issn.1673-4157.2017.01.03]
[6]李博,苏青.晚期糖基化终末产物及其受体与非酒精性脂肪性肝病的
关系[J].国际内分泌代谢杂志,2017,37(03):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
Li Bo,Su Qing..Relationship between advanced glycation end-products and its receptor in nonalcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2017,37(06):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
[7]狄红杰,刘超.饮食干预对非酒精性脂肪性肝病肠道菌群的影响[J].国际内分泌代谢杂志,2017,37(04):254.
Di Hongjie,Liu Chao..Effects of diet interventions on gut microbiota of nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2017,37(06):254.
[8]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(06):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[9]李霞 雷涛.铁过载与代谢性疾病的关系[J].国际内分泌代谢杂志,2018,38(01):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
Li Xia*,Lei Tao..Relationship between iron overload and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(06):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
[10]曹白鸽 董艳.母体妊娠期高脂饮食所致的炎性反应状态对子代的影响[J].国际内分泌代谢杂志,2018,38(02):96.[doi:10.3760/cma.j.issn.1673-4157.2018.02.006]
Cao Baige*,Dong Yan..Effects of inflammatory state on offspring induced by maternal high-fat diet during pregnancy[J].International Journal of Endocrinology and Metabolism,2018,38(06):96.[doi:10.3760/cma.j.issn.1673-4157.2018.02.006]